Neumora Therapeutics, Inc. Common StockNMRANASDAQ
Loading
Operating Expenses Over TimeStrong
Percentile Rank80
3Y CAGR+21.0%
5Y CAGR+20.3%
Year-over-Year Change
Expenses from normal business operations (SG&A, R&D, etc.)
3Y CAGR
+21.0%/yr
Annual compound
5Y CAGR
+20.3%/yr
Consistent
Percentile
P80
Within normal range
vs 5Y Ago
2.5x
Strong expansion
Streak
1 yr
Consecutive declineStrong
| Period | Value | YoY Change |
|---|---|---|
| TTM | $240.60M | -8.7% |
| 2024 | $263.46M | +40.5% |
| 2023 | $187.53M | +38.0% |
| 2022 | $135.87M | -42.7% |
| 2021 | $237.32M | +148.5% |
| 2020 | $95.52M | - |